TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1389192
Drug: Lidocaine inhalation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inhalation 40 mg
Study: 1389192
Drug: Lidocaine inhalation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inhalation 120 mg
Study: 1389192
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) lidocaine 1 mg/kg
Study: 1389192
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation (placebo)
Study: 25945935
Drug: Ultrasound-guided pulsed
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided pulsed radio frequency treatment
Study: 24286801
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of cultured MSCs with hyaluronic acid 3 weeks after surgery
Study: 1411403
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tetracycline, ornidazole, bismuth subcitrate)
Study: 3931154
Drug: Scopolamine (centrally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (centrally active anticholinergic drug) administered in three different intravenous doses
Study: 19891620
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell treatment for cardiac repair
Study: 9391668
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (middle ear pressure changes)
Study: 8430715
Drug: Immunologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunologic therapy with dialyzable leukocyte extract
Study: 8430715
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of immunologic therapy and CBT
Study: 8430715
Drug: Nonspecific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific treatment regimens
Study: 30798674
Drug: Treatment supporters
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment supporters providing medical and social support to PLWHA
Study: 30798674
Drug: Open communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open communication and committed emotional support from treatment supporters
Study: 30798674
Drug: Training and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training and systemic support for treatment supporters
Study: 30798674
Drug: Lack of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack of HIV-related knowledge among treatment supporters
Study: 30115112
Drug: Home-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based self-help metacognitive therapy (Home-MCT) plus usual cardiac rehabilitation
Study: 24411003
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg plus ezetimibe
Study: 20814815
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus enzastaurin (1,250 mg/m² twice daily plus 500 mg/day)
Study: 17551305
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus gemcitabine (docetaxel 75 mg/m2 on day 8 and gemcitabine 1000 mg/m2 on day 1 and day 8 every 3 weeks for 6 cycles)
Study: 15867552
Drug: Intralesional corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional corticosteroid injection (CSI)
Study: 8726539
Drug: Cabergoline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (up to 5 mg daily)
Study: 8726539
Drug: Cabergoline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (10 mg daily in open-label phase)
Study: 8726539
Drug: Cabergoline (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (higher doses)
Study: 1762811
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of a mannitol solution containing 7.5 mg/kg L‐tryptophan
Study: 1762811
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of a mannitol solution containing 15 mg/kg L‐tryptophan
Study: 1762811
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 5% mannitol solution i.v.
Study: 6210867
Drug: Danazol 100
Normalized name: danazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 100 mg/day
Study: 6210867
Drug: Danazol 400
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 400 mg/day
Study: 6210867
Drug: Danazol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (various doses)
Study: 6210867
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg/day) with amenorrhea
Study: 6210867
Drug: Post-treatment follow-up
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment follow-up in infertile patients
Study: 25748293
Drug: Minodronic acid
Normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Minodronic acid 1 mg (single dose)
Study: 25748293
Drug: Minodronic acid
Normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Minodronic acid 1 mg (repeated doses for 7 days)
Study: 25748293
Drug: Minodronic acid
Normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Minodronic acid 4 mg (single dose under fed conditions)
Study: 25748293
Drug: Minodronic acid
Normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Minodronic acid (various doses 1, 2, and 4 mg)
Study: 25675570
Drug: Elongated needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elongated needle therapy at Tiantu (CV 22)
Study: 25675570
Drug: Regular needle
Normalized name: CareOne 1ML 30G 1/2 inch Regular Needle Insulin Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular needle therapy at Tiantu (CV 22)
Study: 17543140
Drug: Acetyl L-carnitine
Normalized name: Nature's Way Acetyl L-Carnitine Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl L-carnitine (LAC) 500 mg, 2 capsules/day plus 500 mg i.m. injection for 2 weeks, then 3 capsules/day for 8 weeks
Study: 17543140
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 capsules/day plus placebo i.m. injection for 2 weeks, then placebo for 8 weeks
Study: 17543140
Drug: Acetyl L-carnitine
Normalized name: Nature's Way Acetyl L-Carnitine Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl L-carnitine (LAC)
Study: 14749760
Drug: Mineral water
Normalized name: mineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral water fortified with folic acid (563 microg/day), vitamins B(6) (1 mg/day), B(12) (7.5 microg/day), cholecalciferol (0.6 microg/day), and calcium (563 mg/day)
Study: 1606348
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg intravenous ciprofloxacin
Study: 1606348
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg intravenous ciprofloxacin
Study: 4003485
Drug: Hypertonic solution
Normalized name: Hypertonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic solution (670 ml Osmol)
Study: 4003485
Drug: Hypotonic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic solution (224 ml Osmol)
Study: 28929521
Drug: Radavirsen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radavirsen 0.5 mg kg-1 to 8 mg kg-1 (single ascending doses)
Study: 28929521
Drug: Radavirsen 8
Normalized name: Radavirsen
DrugBank: Radavirsen (DB15332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radavirsen 8 mg kg-1 (multiple doses)
Study: 28929521
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single ascending doses)
Study: 16446748
Drug: Tissue Monitoring
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue Monitoring System (TMS) - participants weighed themselves daily and received feedback on weight changes via email.
Study: 16446748
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - participants were weighed at the beginning and the end of the semester without daily monitoring.
Study: 11005266
Drug: Cabergoline (CAB)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (CAB) 0.5 mg twice weekly
Study: 11005266
Drug: Quinagolide (QUI)
DrugBank: Quinagolide (DB09097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinagolide (QUI) 75 microg once daily
Study: 1287833
Drug: Procainamide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (25 mg/min, max dose 15 mg/kg)
Study: 1287833
Drug: Digoxin (0.75-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.75-1.0 mg intravenously according to renal function and body weight)
Study: 29771807
Drug: Oral isotonic
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotonic glucose-sodium hydration solution for 40 days postdischarge
Study: 26703919
Drug: Supplemental parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental parenteral nutrition strategy for 7 days post randomisation
Study: 23557411
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 μg subcutaneously every 8 h; n = 32)
Study: 18549361
Drug: Continuous opioid
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous opioid therapy (COT)
Study: 16389581
Drug: Vocational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocational therapy approaches
Study: 10698876
Drug: Six week
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six week domiciliary occupational therapy
Study: 9098588
Drug: Mibefradil added
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mibefradil added to standard therapy for heart failure
Study: 3954110
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus 0.5 ml normal saline (Group 1)
Study: 3954110
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus 0.3 mg epinephrine (Group 2)
Study: 3954110
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus 5 mg phenylephrine (Group 3)
Study: 20634355
Drug: Placebo (interspinous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (interspinous saline, L(3)-L(4))
Study: 18155934
Drug: Exposure plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure plus usual treatment
Study: 18155934
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control plus usual treatment
Study: 18155934
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients treated (pre to post-treatment)
Study: 16177596
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g UWP/d
Study: 12933391
Drug: 5% lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine-prilocaine (EMLA) cream
Study: 14588914
Drug: Routine hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hospital treatment and discharge instructions (control group)
Study: 1991923
Drug: IgE antibody
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE antibody specific for formaldehyde-human serum albumin detected by ELISA in three subjects.
Study: 6109741
Drug: Chlorpheniramine 8
Normalized name: CODEINE 54.3/CHLORPHENIRAMINE 8MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 8 mg (single dose)
Study: 6109741
Drug: Chlorpheniramine 8
Normalized name: CODEINE 54.3/CHLORPHENIRAMINE 8MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 8 mg (seven doses)
Study: 6109741
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg (single dose)
Study: 6109741
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg (seven doses)
Study: 6109741
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chlorpheniramine and cimetidine (seven doses)
Study: 26596670
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus lenalidomide (six cycles of cyclophosphamide [300 mg/m2, days 1, 8, and 15], dexamethasone [40 mg, days 1, 8, 15, and 22], and lenalidomide [25 mg, days 1-21])
Study: 26596670
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan (200 mg/m2) and ASCT
Study: 26596670
Drug: Lenalidomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (10 mg, days 1-21) plus prednisone (50 mg, every other day)
Study: 26596670
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus lenalidomide
Study: 9215300
Drug: 0.1 mU.kg‐1.min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mU.kg‐1.min‐1 euglycemic insulin clamp
Study: 9215300
Drug: 0.4 mU.kg‐1.min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mU.kg‐1.min‐1 euglycemic insulin clamp
Study: 9215300
Drug: iv 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv 0.9% NaCl infusion after oral acipimox administration (250 mg)
Study: 8573453
Drug: Chemopreventive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemopreventive agents such as retinoids and tamoxifen
Study: 2223687
Drug: Norethisterone acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone acetate, 1 mg (group A)
Study: 2223687
Drug: Norethisterone acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone acetate, 0.5 mg (group B)
Study: 2223687
Drug: Megestrol acetate,
Normalized name: megestrol acetate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol acetate, 5 mg (group C)
Study: 2223687
Drug: Megestrol acetate,
Normalized name: megestrol acetate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol acetate, 2.5 mg (group D)
Study: 573602
Drug: Kallikrein (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kallikrein (600 units porcine pancreatic kallikrein daily for 7 weeks)
Study: 573602
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 7 weeks)
Study: 26801909
Drug: Artemisinin combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin combination therapy (ACT)
Study: 21947320
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/day plus modafinil 200 mg/day
Study: 17156104
Drug: Sitagliptin 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 5, 12.5, 25 or 50 mg b.i.d.
Study: 17156104
Drug: Glipizide 5
Normalized name: glipizide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 5 mg/day (titrated up to 20 mg/day)
Study: 8372418
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of immunosuppressants in adults
Study: 8372418
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of immunosuppressants in children
Study: 20068423
Drug: Maintenance training
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance training (MT) for 1 year, including weekly supervised training for the first 6 months, bi-weekly supervised training for the next 6 months, and no supervised training for the last 6 months.
Study: 7489965
Drug: Recombinant interferon‐alfa2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alfa2b 5 MU/m2 thrice weekly for 4 months, continued up to 12 months if ALT reduced by at least 50%
Study: 1683682
Drug: H. influenzae
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. influenzae type b polysaccharide (PRP) vaccine
Study: 1683682
Drug: Polysaccharide‐mutant diphtheria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide‐mutant diphtheria toxoid conjugate vaccine (PRP‐CRM)
Study: 31894038
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition support therapy combined with antibiotics (azithromycin plus cefuroxime sodium)
Study: 31894038
Drug: Parenteral nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutritional support therapy combined with antibiotics (azithromycin plus cefuroxime sodium)
Study: 27052036
Drug: Melatonin cream
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin cream 12.5% applied on 80% of body surface area
Study: 22250853
Drug: Positive response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Positive response to MDD treatment
Study: 22250853
Drug: Initial MDD
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial MDD treatment (CBT, FLX, COMB, PBO)
Study: 22250853
Drug: Prior involvement
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior involvement with alcohol or drugs
Study: 11769996
Drug: Prednisone tablets
Normalized name: Prednisone Tablets
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone tablets
Study: 2503490
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg, orally)
Study: 28120497
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg (with optional uptitration to 300 mg)
Study: 29911577
Drug: Experimental knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental knee pain (hypertonic saline injection)
Study: 29911577
Drug: Control (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isotonic saline injection)
Study: 21227540
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intravenous metoclopramide
Study: 18306984
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment with pantoprazole (40 mg twice daily), amoxicillin (1000 mg twice daily), and clarithromycin (500 mg) for 7 days
Study: 18306984
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment with ranitidine bismuth citrate (400 mg twice daily), metronidazole (250 mg twice daily), and clarithromycin (500 mg) for 7 days
Study: 18306984
Drug: Third-line quadruple
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-line quadruple therapies with pantoprazole + amoxicillin and tetracycline (500 mg four times daily) and either nitrofurantoin (100 mg three times daily) or bismuth subsalicylate (120 mg four times daily)
Study: 11058672
Drug: Inhaled zanamivir
Normalized name: zanamivir Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled zanamivir (10 mg twice a day for 5 days for index cases, 10 mg once a day for 10 days for family members)
Study: 3914703
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/qd
Study: 31251548
Drug: Kamedis Eczema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kamedis Eczema Therapy Cream (tested product)
Study: 28918674
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Fruitflow®
Study: 25284142
Drug: High-dose proton-pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose proton-pump inhibitors (HD PPIs)
Study: 22409309
Drug: Eltrombopag (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (12.5 mg)
Study: 20174834
Drug: landiolol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: landiolol 0.1 mg/kg
Study: 20174834
Drug: nicardipine 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicardipine 0.02 mg/kg
Study: 16018750
Drug: Vitamin-B complex
Normalized name: vitamin B complex
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin-B complex supplementation (50 mg of thiamine HCl, riboflavin, niacinamide, d-calcium pantothenate, pyridoxine HCl; 50 microg each of d-biotin and cyanocobalamin; and 400 mcg of folate) for 30 days after AFS
Study: 12454519
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (Group B)
Study: 7499110
Drug: Sulofenur 640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulofenur 640 mg/M2
Study: 7499110
Drug: Sulofenur 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulofenur 800 mg/M2
Study: 7499110
Drug: Sulofenur 960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulofenur 960 mg/M2
Study: 1959341
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3) 6 g/day for 3 months
Study: 6765542
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin combination with 20% regular and 80% NPH
Study: 6765542
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin combination with 30% regular and 70% NPH
Study: 6765542
Drug: PPI 30/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI 30/70 combination